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Abstract
Background: Multiple lines of evidence suggest innate immune response pathways to be involved in the development of
obesity-associated diabetes although the molecular mechanism underling the disease is unknown. Recent observations
suggest that saturated fatty acids can act as a ligand for toll-like receptor (TLR) 4, which is thought to mediate obesity-
associated insulin resistance. Myeloid differentiation factor 88 (MyD88) is an adapter protein for TLR/IL-1 receptor signaling,
which is involved in the activation of inflammatory pathways. To evaluate molecular mechanisms linking obesity-associated
diabetes down-stream of TLR4, we investigated physiological role of MyD88 in high-fat diet (HFD)-induced obesity.
Methodology/Principal Findings: In the present study, we found MyD88-deficient mice fed a HFD had increased circulating
levels of insulin, leptin and cholesterol, as well as liver dysfunction (increased induction of ALT levels, increased activation of
JNKandcleavageofPARP),whichwerelinkedtotheonsetofseverediabetes.Ontheotherhand,TNF-awouldnotbeinvolved
in HFD-induced diabetes in MyD88-deficient mice, because TNF-a level was attenuated in MyD88-deficient mice fed with HFD.
Conclusions/Significance: The present finding of an unexpected role for MyD88 in preventing diabetes may provide a
potential novel target/strategy for treating metabolic syndrome.
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Introduction
Multiple lines of evidence suggest innate immune response
pathways to be involved in the development of obesity-associated
diabetes. However, the molecular mechanism underling the
disease is unknown [1].
Excess accumulation of fatty acids is a characteristic of
metabolic disease. Toll-like receptor 4 (TLR4) is known to play
a critical role in the activation of innate immune responses by
recognizing lipopolysaccharide. Interestingly, recent observations
suggest that saturated fatty acids can act as a ligand for TLR4
[2,3]. TLR4 deficient/mutated mice have been shown to protect
from obesity-associated insulin resistance [3-7]. Collectively, these
findings indicate TLR4-mediated signaling would exacerbate
metabolic syndrome by enhancing inflammation. However, the
intracellular mechanisms of TLR4-mediated metabolic disease are
unknown. Thus, in the present study, we focused on by possible
functional role of myeloid differentiation factor 88 (MyD88), an
essential adapter protein for TLR/interleukin (IL)-1 receptor
signaling [8,9], in metabolic disease. MyD88 is originally isolated
as myeloid differentiation primary response gene, which is induced
in M1 myeloleukemic cells in response to interleukin-6 [10].
Subsequently, MyD88 was found to be related to the interleukin-1
receptor (IL-1R) family including Toll/TLR protein, which is
homologous to that of IL-1R [11]. Finally, it has been
demonstrated that signaling via TLR4 employs MyD88 as an
adaptor protein, that induces activation of NFkB through
interleukin 1 receptor-associated kinase (IRAK) kinase and TNF
receptor-associated factor 6 (TRAF6) [12]. Such activation is
essential for the induction of innate immune responses.
The purpose of this study was to test the physiological role of
MyD88 in the state of metabolic disease using MyD88-deficient
mice. As saturated fatty acids-induced activation of TLR4 is
involved in enhancing metabolic disease, MyD88-deficient mice
would be expected to attenuate obesity-associated diabetes.
However, contrary to expectations, we found that these mice
exhibit severe diabetic phenotype.
Results
MyD88-deficiency exacerbates diabetes without
affecting body weight or adiposity
To assess whether MyD88 is involved in glucose metabolism, we
performed the glucose tolerance test (GTT) using age-matched
systemic MyD88-deficient and control mice. First, we measured
fasted blood glucose levels and found them to be increased in
MyD88-deficient mice on either a normal chow diet (NCD) or a
high-fat diet (HFD) (Figure 1A–D). In addition, GTT markedly
raised blood glucose levels in MyD88-deficient mice compared to
the controls (Figure 1A–D). The increase in blood glucose differed
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(Figure 1A–D). However, no genotype-dependent differences in
body weight gain (Figure 2AB) or visceral fat content (Figure 2CD)
were observed in the NCD or HFD-fed state, suggesting that the
differenceincirculatingglucoselevelswasnotdependentonobesity.
In addition, no differences in food intake (Figure 2EF) or locomotor
activity (Figure 2G) wereobserved in either genotypes. These results
are unexpected because impaired function/expression of TLR4 has
been reported to protect against obesity-associated diabetes [3–5].
Consequently, we measured circulating levels of insulin and leptin
by ELISA, and found them to be elevated in MyD88-deficient mice
(Figure 3AB), suggesting type 2 diabetes.
Increased circulating level of cholesterol and JNK
activation in MyD88-deficient mice fed with HFD
As the activation of c-Jun amino-terminal kinase (JNK) in the
liver plays a critical role in the development of diabetes [13,14], we
next examined whether levels of phosphorylated JNK are altered
in MyD88-deficient mice. Consistent with a previous report [14],
we observed an increase in the phosphorylation of JNK in normal
mice fed a HFD (Figure 4A). To our surprise, the increase was
drastically enhanced in MyD88-deficient mice on the HFD
(Figure 4A). The result was unexpected because MyD88-deficient
mice are resistant to the LPS-induced activation of JNK [8].
To identify the mechanisms linking JNK’s activation in MyD88-
deficient mice fed the HFD, we examined the level of tumor
necrosis factor-a (TNF-a) in the liver, as TNF-ais involved in the
activation [15]. The level of mRNA encoding TNF-awas elevated
in HFD-fed control mice (Figure 4B). However, this increase was
markedly inhibited in MyD88-deficient mice on the HFD
(Figure 4B). Thus, TNF-aexpression is induced via a MyD88-
dependent pathway in mice fed a HFD. Moreover, TNF-amay not
be involved in activating JNK in such mice. To identify the factor
responsible for activating JNK in MyD88-deficient mice, we next
Figure 1. MyD88-deficiency increases the risk of diabetic mellitus. Both genotypes were fed a NCD until 6 weeks of age and then fed a NCD
or HFD for 10 weeks. Mice were fasted for 16 h (from 18:00 to 10:00) and subjected to a glucose tolerance test (GTT). We measured circulating levels
of glucose at the time indicated (0.5-4 h). (A) NCD-fed mice. (B) HFD-fed mice. (C) NCD- and HFD-fed mice, which were fasted for 16 h. (D) Glucose
levels after GTT (2 h time point) of each genotype of mice fed the NCD or HFD. n=6,12/group. *p,0.05, **p,0.01, ***p,0.001 v.s. control mice.
doi:10.1371/journal.pone.0012537.g001
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JNK’s activation [16]. We observed an increase in cholesterol
(total, free and esterified cholesterol) levels in HFD-fed normal
mice and a marked increase in MyD88-deficient mice fed the
HFD (Figure 5A–C). We also found that low density lipoprotein
receptor (LDLR) was drastically up-regulated in the liver sample of
MyD88-deficient mice fed the HFD (Figure 5D), suggesting
positive feedback regulation against the increased circulating levels
of cholesterols to remove them [17,18]. Interestingly, transcrip-
tional level of HMG-CoA reductase, the rate-limiting enzyme of
cholesterol biosynthesis [19], was up-regulated in the liver sample
of MyD88-deficient mice fed the HFD (Figure 5E). Thus, the
increased level of cholesterol observed in theses mice would be due
to the induction of HMG-CoA reductase. Moreover, these results
suggest that the increased levels of cholesterol in MyD88-deficient
mice to be responsible for the activation of JNK.
Liver dysfunction in MyD88-deficient mice fed with HFD
JNK’s activation results in apoptosis [20]. Thus, to assess
whether these differences would result in liver dysfunction, we next
measured cleavage of poly (ADP-ribose) polymerase (PARP), an
indicator of the apoptotic state, in liver samples of both genotypes
of NCD and HFD-fed mice. As shown in Figure 6A, we found an
increase in PARP cleavage in MyD88-deficient mice fed the HFD.
Figure 2. MyD88-deficiency did not affect body weight, adiposity, food intake or locomotor activities. (A) Body weight gain was
measured in control and MyD88-deficient mice. Both genotypes were fed a NCD until 6 weeks of age and then fed a NCD or HFD for 10 weeks. NCD
(n=21–29) and HFD (n=20–26)-fed mice were examined at the age of 16 weeks. (B) Control and MyD88-deficient mice were fed the HFD from the
age of 6 weeks and body weight gain was measured every week (10 weeks). (n=16–23) (C) Visceral fat was measured at the age of 18 weeks. NCD
(n=8) HFD (n=6–8) (D) Typical photograph of each genotype of mice fed the NCD or HFD. (EF) Fifteen hours (From19:00 to 10:00) of food intake
was measured in each genotype of mice fed the NCD or HFD at the age of 16 weeks. n=11–13/group (G) Locomotor activities (5 min) were
measured in each genotype of mice fed the NCD or HFD at the age of 16 weeks. n=11–14/group.
doi:10.1371/journal.pone.0012537.g002
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(ALT), a marker of hepatic injury, was significantly elevated in
MyD88-deficient mice fed the HFD compared with normal mice
(Figure 6B). Together, these findings indicate that the diabetic
phenotype observed in Myd88-deficient mice was due at least in
part to increased apoptosis in the liver possibly mediated via
hypercholesterolemia.
Discussion
Increasing evidence indicate the link among obesity, diabetes
and inflammatory pathways in developing metabolic diseases. As
saturated fatty acids-induced activation of TLR4 is involved in
enhancing metabolic disease, we expected that MyD88 would
exacerbate metabolic disease. However, to our surprise, we found
that MyD88 is involved in protecting against diabetes mellitus. We
found that MyD88-deficient mice fed with high fat diet develop
severe diabetes. From these observations, we are next interested in
investigating mechanisms of diabetes observed in MyD88-
deficiency. As TNF-ais involved in the development of insulin
resistance [21–23] and that MyD88 is involved in activating
inflammatory signals [8,24], we measured liver TNF-alevels in
these mice. We found that HFD-induced induction of this cytokine
was impaired in MyD88-deficient mice. Collectively these results
indicate that TNF-ais not involved in diabetes observed in
MyD88-deficient mice. Then, what is the responsible factor
exacerbating diabetes in MyD88 deficiency? In the present study,
we investigated possible involvement of cholesterol in the
development of such phenotype and found that circulating
cholesterol levels as well as liver LDLR and HMG-CoA levels
were drastically increased in MyD88-deficient mice fed a HFD.
Elevated levels of cholesterol will increase apoptosis [25]. We
observed JNK activation and liver dysfunction (PARP cleavage
and increase in ALT levels) in MyD88-deficient mice fed a HFD.
Figure 3. Increased circulating levels of insulin and leptin in MyD88-deficient mice. (A) Plasma insulin was measured in each genotype fed
the NCD (n=9–10) or HFD (n=10–15) at the age of 16 weeks. *p,0.05 (B) Plasma leptin was measured in each genotype fed the NCD (n=9–16) or
HFD (n=11–12) at the age of 16 weeks. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0012537.g003
Figure 4. JNK activation without affecting TNF-a levels in MyD88-deficient mice fed the HFD. (A) Western blot analysis of p-JNK in liver
samples at the age of 18 weeks. Each genotype of mice was fed the NCD (n=7) or HFD (n=6–8). ***p,0.001 (B) mRNA level of TNF-a was measured
in liver samples at the age of 18 weeks. (n=6–8) **p,0.01.
doi:10.1371/journal.pone.0012537.g004
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measured at the age of 18 weeks. (A) Free cholesterol, (B) esterified cholesterol and (C) total cholesterol levels. Each genotype of mice was fed the
NCD (n=8) or HFD (n=6–7). **p,0.01, ***p,0.001 (DE) mRNA levels of LDLR and HMG-CoA reductase (HMG-CoA R) were measured in liver samples
at the age of 18 weeks. (n=6–8) *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0012537.g005
Figure 6. MyD88-deficient mice fed the HFD developed liver dysfunction. (A) Western blot analysis of cleaved PARP in liver samples at the
age of 18 weeks. Each genotype of mice was fed the NCD (n=7) or HFD (n=6–8). **p,0.01 (B) Serum ALT levels were measured at the age of 18
weeks. Each genotype of mice was fed the NCD (n=8) or HFD (n=6–7). **p,0.01.
doi:10.1371/journal.pone.0012537.g006
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diabetes observed in MyD88-deficient mice. It would be useful to
analyze the double knockout mice for MyD88 and cholesterol
related gene such as HMG-CoA reductase to conform the results
more directly.
Intriguingly, the deletion of MyD88 restricted to the central
nervous system had been reported to protect against HFD-induced
impairment of glucose tolerance [26]. Taking into account the
present contrasting finding that a systemic deficiency of MyD88 in
mice exacerbated the HFD-induced impairment of glucose
tolerance, we speculate that the physiological role of MyD88 differs
among tissues expressed. Considering the role of liver on glucose
homeostasis, the important role of liver JNK or IkBk i n a s e - b in the
development of diabetes has been reported [27–29]. On the other
hand, the important role of central nervous system (CNS) on
regulation of glucose homeostasis has been suggested [30].
Interestingly, although insulin action at CNS and peripherally can
both reduce glucose levels, peripheral action of insulin is an anabolic
(stimulates nutrient storage), which contrast with its catabolic
function at CNS (inhibits food intake and stimulates energy
expenditure)[31]. Thus, the metabolic action of CNS and peripheral
organs wouldbe different. It is thereforeinteresting subjectto further
analyze the pathophysiological role of MyD88 in the brain v.s.
periphery. In addition, it will be needed to investigate what type of
cell is responsible for diabetes observed in MyD88-deficiency. The
use of conditional knockout mouse (such as liver-specific knockout
mouse) would be useful to answer these questions. Importantly,
MyD88-deficiency in human subjects has been reported [32]. At
present, it is unknown whether MyD88-deficient human subjects are
prone to diabetes and it will be an open questions.
The present results indicate an unanticipated important link
between MyD88 and the development of diabetes mellitus. Our
findings would provide a molecular basis for understanding




Adult male C57BL/6CrSlc mice (wild type, WT) and MyD88-
deficient mice (MyD88
2/2) mice were used in the present study.
The MyD88-deficient mice (C57BL/6 Cr Slc back ground) were
kindly provided by Dr. Shizuo Akira (Department of Host defense,
Research Institute for Microbial Disease, Osaka University). The
C57BL/6 Cr Slc control mice were obtained from SLC
(Hamamatsu, Japan). Mice were maintained in a room at 22–
24uC under a constant day-night rhythm and given food and
water, ad libitum. They were fed either a normal chow diet (NCD:
MF diet; Oriental Yeast, Tokyo, Japan) or a high-fat diet (HFD:
D12492; Research diets, NJ). The NCD and HFD contained 5.3%
and 35% fat, respectively. All animal experiments were carried out
in accordance with the NIH Guide for Care and Use of
Laboratory Animals and approved by the animal care and use
committee at Hiroshima University (Permit number: A10-41).
Glucose Tolerance Test
The Glucose Tolerance Test was performed with mice fasted
16 h (18:00–10:00). After measuring the fasted blood glucose level,
we injected glucose (2 g/kg, 15 ml/kg) through the intraperitoneal
route. Blood glucose levels were measured after 0.5, 1, 2 and 4 h
using NIPRO Freestyle Freedom (Osaka, Japan).
Body Weight
Body weight was measured once a week at 16:00–17:00.
Food intake
Both genotypes of mice were housed individually prior to the
experiment. Food intake was measured at the end of the study
period of 16 weeks.
Locomotor activities
An open field locomotor test was performed to monitor
locomotor activities. Mice were placed at the centre of a cubic
chamber (48648648 cm). The animal’s horizontal movements
(5 min) were measured by automatic actography (SCANET MV-
10; Melquest, Toyama, Japan). The test room was dimly
illuminated with indirect white lighting.
Measurement of insulin and leptin levels
Blood samples (including EDTA) were taken by decapitation and
centrifuged (4uC, 3,000 rpm, 15 min) to obtain plasma samples.
Plasmainsulin(Morinaga;Tokyo,Japan) and leptin (R& D systems;
MN) levels were measured by ELISA according to the manufac-
turer’s guidelines.
Measurement of cholesterol and ALT levels
Blood samples were taken by decapitation and stood for 2 hours
at room temperature. The samples were then centrifuged (4uC,
3,000 rpm, 15 min) to obtain serum. Serum cholesterol and ALT
levelswere measuredat SRL, Inc. (Tokyo, Japan). Cholesterol levels
were measured by HDAOS and DAOS methods. ALT levels were
measured by the UV method.
Preparation of liver samples
Mice were sacrificed by decapitation and the liver was quickly
removed and rapidly dissected on an ice-cold plate. The samples
were snap-frozen in liquid nitrogen and stored at 280uC prior to
use.
Western blot analysis
Western blotting was performed as described previously [33].
Liver samples were homogenized with 100 revolutions in a glass
homogenizer containing 10 mM HEPES–NaOH (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 10 mM NaF,
10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF and 1%
NP-40. The samples were then centrifuged at 20,630 g for 45 min
at 4uC and the supernatants were collected. Laemmli buffer was
added to the samples and boiled for 3 min. The samples were
fractionated by SDS-PAGE (100–200 mg/lane) and transferred at
4uC to nitrocellulose membranes. The membranes were blocked
and incubated with an anti-phospho (Thr183/Tyr185)-JNK (Cell
signaling; 1:1,000), anti-PARP (Santa Cruz Biotechnology;
1:1,000) or anti-GAPDH (Chemicon; 1:1,000) antibody at 4uC.
The membranes were washed and then incubated with an anti-
horseradish peroxidase-linked antibody (GE Healthcare). Peroxi-
dase was detected using an ECL system (GE Healthcare). The
density of bands was measured using Image J 1.37v (Wayne
Rasband, NIH) software.
Gene expression analysis
Tissue samples were homogenized at 10,000 rpm using a
polytron homogenizer in TriPure Isolation Reagent (Roche
Diagnostics) and total RNA was isolated according to the
manufacturer’s protocol. cDNA was synthesized from 2 mgo f
total RNA by reverse transcription using 25 U of Superscript
Reverse Transcriptase III(Invitrogen) and 0.25 mg of Oligo(dt)12–
18 primer (Invitrogen) in a 20-ml reaction mixture containing First-
Strand Buffer (Invitrogen), 1 mM dNTP mix, 10 mM DTT, and
MyD88 and Diabetes
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(Invitrogen). Total RNA and the Oligo (dt) 12–18 primer were
pre incubated at 70uC for 10 min prior to the reverse
transcription. After incubation for 1.5 h at 46uC, the reaction
was terminated by incubating samples for 15 min at 70uC.
For PCR amplification, 1.2 ml of cDNA was added to 10.8 mlo f
a reaction mix containing 0.2 mM of each primer, 0.2 mM of
dNTP mix, 0.6 U of Taq polymerase (Roche Diagnostics), and
reaction buffer. PCR was performed in a DNA Thermal Cycler
(MJ Research, PTC-220). The following primer sequences were
used: TNF-a; upstream, 59–cac gtc gta gca aac cac caa-39, and
downstream, 59-ccc att ccc ttc aca gag caa-39, LDLR; upstream,
59–tcc aat caa ttc agc tgt gg-39, and downstream, 59-gag cca tct agg
caa tct cg-39, HMG-CoA reductase; upstream, 59–agc ttg ccc gaa
ttg tat gtg-39, and downstream, 59-tct gtt gtg aac cat gtg act tc-39,
GAPDH; upstream, 59-aaa ccc atc acc atc ttc cag-39 and
downstream, 59-agg ggc cat cca cag tct tct-39. The PCR products
(10 ml) were resolved by electrophoresis in an 8% polyacrylamide
gel in TBE buffer. The gel was stained with ethidium bromide and
photographed under ultraviolet light. The density of bands was
measured using Image J 1.37v (Wayne Rasband, NIH) software.
Statistics
Results are expressed as the mean 6 S.E.. Statistical analyses
were performed using Student’s t-test.
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